Production (Stage)
Revelation Biosciences, Inc.
REVB
$3.00
$0.134.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.24M | 1.15M | 965.70K | 1.13M | 1.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10M | 1.75M | 1.80M | 2.52M | 1.90M |
| Operating Income | -2.10M | -1.75M | -1.80M | -2.52M | -1.90M |
| Income Before Tax | -2.05M | -1.73M | -2.24M | -8.39M | -2.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.05M | -1.73M | -2.24M | -8.39M | -2.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.05M | -1.73M | -2.24M | -8.39M | -2.68M |
| EBIT | -2.10M | -1.75M | -1.80M | -2.52M | -1.90M |
| EBITDA | -2.09M | -1.75M | -1.79M | -2.52M | -1.90M |
| EPS Basic | -6.34 | -14.94 | -40.15 | -246.27 | -118.10 |
| Normalized Basic EPS | -3.96 | -9.34 | -25.09 | -153.92 | -73.81 |
| EPS Diluted | -6.34 | -14.94 | -40.32 | -246.27 | -118.10 |
| Normalized Diluted EPS | -3.96 | -9.34 | -25.09 | -153.92 | -73.81 |
| Average Basic Shares Outstanding | 323.80K | 115.50K | 55.80K | 34.10K | 22.70K |
| Average Diluted Shares Outstanding | 323.80K | 115.50K | 55.80K | 34.10K | 22.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |